Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $21.00 Consensus Price Target from Brokerages

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $21.00.

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of Atara Biotherapeutics in a report on Saturday, September 27th.

Insider Activity at Atara Biotherapeutics

In other news, major shareholder Innovation Ltd Panacea bought 55,000 shares of the stock in a transaction dated Friday, August 15th. The stock was bought at an average price of $12.19 per share, for a total transaction of $670,450.00. Following the purchase, the insider directly owned 1,405,000 shares in the company, valued at $17,126,950. This trade represents a 4.07% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.00% of the company’s stock.

Institutional Trading of Atara Biotherapeutics

A number of hedge funds have recently modified their holdings of ATRA. Raymond James Financial Inc. purchased a new stake in shares of Atara Biotherapeutics in the 2nd quarter worth about $31,000. Marshall Wace LLP bought a new stake in Atara Biotherapeutics during the second quarter worth about $327,000. Geode Capital Management LLC grew its holdings in Atara Biotherapeutics by 2.5% in the second quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company’s stock worth $464,000 after purchasing an additional 1,457 shares during the period. Staley Capital Advisers Inc. increased its stake in shares of Atara Biotherapeutics by 60.0% during the first quarter. Staley Capital Advisers Inc. now owns 80,000 shares of the biotechnology company’s stock valued at $475,000 after purchasing an additional 30,000 shares in the last quarter. Finally, EcoR1 Capital LLC lifted its holdings in shares of Atara Biotherapeutics by 7.7% during the first quarter. EcoR1 Capital LLC now owns 573,183 shares of the biotechnology company’s stock valued at $3,405,000 after purchasing an additional 41,049 shares during the last quarter. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Price Performance

ATRA opened at $14.41 on Friday. The stock’s 50 day simple moving average is $12.27 and its 200 day simple moving average is $9.31. The firm has a market cap of $101.16 million, a price-to-earnings ratio of -33.51 and a beta of 0.25. Atara Biotherapeutics has a 1 year low of $5.01 and a 1 year high of $18.70.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.51. The firm had revenue of $17.58 million for the quarter, compared to analysts’ expectations of $4.23 million. Atara Biotherapeutics had a net margin of 3.07% and a negative return on equity of 8.34%. As a group, sell-side analysts anticipate that Atara Biotherapeutics will post -10.39 EPS for the current year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.